Elite Pharmaceuticals Inc (ELTP)
0.5098
0.00 (0.00%)
USD |
OTCM |
Nov 05, 15:59
Elite Pharmaceuticals Research and Development Expense (Annual): 6.883M for March 31, 2024
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.883M |
| March 31, 2023 | 6.200M |
| March 31, 2022 | 4.051M |
| March 31, 2021 | 5.112M |
| March 31, 2020 | 5.532M |
| March 31, 2019 | 7.600M |
| March 31, 2018 | 9.621M |
| March 31, 2017 | 8.302M |
| March 31, 2016 | 12.43M |
| March 31, 2015 | 14.73M |
| March 31, 2014 | 3.959M |
| March 31, 2013 | 0.9752M |
| March 31, 2012 | 1.736M |
| Date | Value |
|---|---|
| March 31, 2011 | 1.385M |
| March 31, 2010 | 0.7944M |
| March 31, 2009 | 3.631M |
| March 31, 2008 | 5.796M |
| March 31, 2007 | 6.086M |
| March 31, 2006 | 4.344M |
| March 31, 2005 | 2.699M |
| March 31, 2004 | 2.075M |
| March 31, 2003 | 2.014M |
| March 31, 2002 | 1.609M |
| March 31, 2001 | 1.476M |
| March 31, 2000 | 1.989M |
| March 31, 1999 | 1.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.051M
Minimum
2022
6.883M
Maximum
2024
5.556M
Average
5.532M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Biomarin Pharmaceutical Inc | 746.77M |
| BioCardia Inc | 7.726M |
| Zevra Therapeutics Inc | 39.81M |
| Verrica Pharmaceuticals Inc | 20.30M |
| Terns Pharmaceuticals Inc | 63.50M |